The Catalogue of Somatic Mutations in Cancer (COSMIC).

PubWeight™: 16.09‹?› | Rank: Top 0.1% | All-Time Top 10000

🔗 View Article (PMC 2705836)

Published in Curr Protoc Hum Genet on April 01, 2008

Authors

S A Forbes1, G Bhamra, S Bamford, E Dawson, C Kok, J Clements, A Menzies, J W Teague, P A Futreal, M R Stratton

Author Affiliations

1: Wellcome Trust Genome Campus, Hinxton, United Kingdom.

Articles citing this

(truncated to the top 100)

Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72

Circos: an information aesthetic for comparative genomics. Genome Res (2009) 40.02

Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 34.13

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res (2010) 25.55

Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08

Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res (2011) 10.99

Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83

The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature (2010) 10.04

COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res (2009) 9.59

Somatic coding mutations in human induced pluripotent stem cells. Nature (2011) 9.50

The UCSC Genome Browser database: extensions and updates 2013. Nucleic Acids Res (2012) 9.02

Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46

The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol (2012) 7.32

WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer (2013) 6.64

Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature (2015) 5.50

Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev (2009) 5.21

MuSiC: identifying mutational significance in cancer genomes. Genome Res (2012) 4.73

An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet (2013) 4.69

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res (2010) 4.50

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature (2013) 4.43

Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science (2013) 4.42

Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A (2011) 4.15

Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev (2010) 3.77

The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer (2012) 3.75

Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer (2010) 3.74

Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet (2011) 3.66

Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res (2010) 3.24

The Human Gene Mutation Database: providing a comprehensive central mutation database for molecular diagnostics and personalized genomics. Hum Genomics (2009) 3.24

Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol (2010) 3.15

Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet (2011) 3.10

Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res (2012) 3.07

Making sense of cancer genomic data. Genes Dev (2011) 3.01

High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer (2006) 2.97

Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature (2012) 2.96

Disease-associated XMRV sequences are consistent with laboratory contamination. Retrovirology (2010) 2.90

Data mining using the Catalogue of Somatic Mutations in Cancer BioMart. Database (Oxford) (2011) 2.84

Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet (2012) 2.71

Identification of fusion genes in breast cancer by paired-end RNA-sequencing. Genome Biol (2011) 2.64

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood (2014) 2.54

Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci Transl Med (2013) 2.30

Mutational spectra of human cancer. Hum Genet (2009) 2.26

Targeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced pluripotent stem cell clones. Cell Stem Cell (2014) 2.24

Kinase mutations in human disease: interpreting genotype-phenotype relationships. Nat Rev Genet (2010) 2.14

Background mutations in parental cells account for most of the genetic heterogeneity of induced pluripotent stem cells. Cell Stem Cell (2012) 2.11

Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet (2013) 2.05

Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis. Nat Genet (2011) 2.02

The role of BRAF V600 mutation in melanoma. J Transl Med (2012) 2.00

An overview of the c-MET signaling pathway. Ther Adv Med Oncol (2011) 1.95

Monoallelic but not biallelic loss of Dicer1 promotes tumorigenesis in vivo. Cell Death Differ (2009) 1.92

A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer (2010) 1.91

Realizing the promise of cancer predisposition genes. Nature (2014) 1.84

Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR. PLoS One (2011) 1.78

Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas. Nat Biotechnol (2009) 1.76

Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clin Cancer Res (2012) 1.74

mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation. Cancer Cell (2015) 1.70

KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol (2013) 1.68

Tissue of origin determines cancer-associated CpG island promoter hypermethylation patterns. Genome Biol (2012) 1.63

Detection of low prevalence somatic mutations in solid tumors with ultra-deep targeted sequencing. Genome Biol (2011) 1.60

Copy number variations and cancer. Genome Med (2009) 1.59

Targeting BRAF for patients with melanoma. Br J Cancer (2010) 1.56

Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin. Genome Med (2014) 1.55

Improving the efficiency of genomic loci capture using oligonucleotide arrays for high throughput resequencing. BMC Genomics (2009) 1.55

Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med (2012) 1.55

MelanomaDB: A Web Tool for Integrative Analysis of Melanoma Genomic Information to Identify Disease-Associated Molecular Pathways. Front Oncol (2013) 1.53

Invasive three-dimensional organotypic neoplasia from multiple normal human epithelia. Nat Med (2010) 1.52

Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet (2015) 1.47

CRAVAT: cancer-related analysis of variants toolkit. Bioinformatics (2013) 1.43

Molecular prescreening to select patient population in early clinical trials. Nat Rev Clin Oncol (2012) 1.40

Genetic studies in intellectual disability and related disorders. Nat Rev Genet (2015) 1.40

Preferential Allele Expression Analysis Identifies Shared Germline and Somatic Driver Genes in Advanced Ovarian Cancer. PLoS Genet (2016) 1.39

Analytical methods for inferring functional effects of single base pair substitutions in human cancers. Hum Genet (2009) 1.39

Mutational landscape of basal cell carcinomas by whole-exome sequencing. J Invest Dermatol (2013) 1.38

Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene (2010) 1.36

Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. J Clin Invest (2010) 1.35

PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet (2014) 1.34

A bioinformatics workflow for variant peptide detection in shotgun proteomics. Mol Cell Proteomics (2011) 1.34

NPHP4, a cilia-associated protein, negatively regulates the Hippo pathway. J Cell Biol (2011) 1.34

STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. PLoS One (2012) 1.33

AMPKα modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer. Cancer Res (2012) 1.31

Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T. Proc Natl Acad Sci U S A (2010) 1.30

Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia. PLoS Genet (2013) 1.29

Algorithms and semantic infrastructure for mutation impact extraction and grounding. BMC Genomics (2010) 1.29

A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097. Elife (2015) 1.28

DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset. PLoS One (2010) 1.26

Evolution of the cancer genome. Trends Genet (2012) 1.22

Variant association tools for quality control and analysis of large-scale sequence and genotyping array data. Am J Hum Genet (2014) 1.21

Genetic risk factors for melanoma. Hum Genet (2009) 1.21

Prospective enterprise-level molecular genotyping of a cohort of cancer patients. J Mol Diagn (2014) 1.21

Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling. J Biol Chem (2012) 1.20

RIPK1- and RIPK3-induced cell death mode is determined by target availability. Cell Death Differ (2014) 1.20

Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res Treat (2011) 1.19

Bi-directional SIFT predicts a subset of activating mutations. PLoS One (2009) 1.19

CHASM and SNVBox: toolkit for detecting biologically important single nucleotide mutations in cancer. Bioinformatics (2011) 1.18

EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma. Cell Oncol (Dordr) (2012) 1.18

New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res (2010) 1.17

Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation. Haematologica (2013) 1.17

Characterizing mutational heterogeneity in a glioblastoma patient with double recurrence. PLoS One (2012) 1.16

Functional importance of Dicer protein in the adaptive cellular response to hypoxia. J Biol Chem (2012) 1.15

Large-scale mass spectrometric detection of variant peptides resulting from nonsynonymous nucleotide differences. J Proteome Res (2013) 1.14

Cancer missense mutations alter binding properties of proteins and their interaction networks. PLoS One (2013) 1.14

Articles by these authors

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science (1994) 36.53

The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer (2004) 12.35

A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature (1998) 10.35

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med (2013) 8.89

Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med (2011) 7.89

Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst (1999) 6.48

Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06

COSMIC 2005. Br J Cancer (2006) 5.07

Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet (1995) 4.86

Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature (1994) 4.78

A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer (2002) 4.18

Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet (1997) 4.16

Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet (1996) 3.56

Positive control and autogenous regulation of the nifLA promoter in Klebsiella pneumoniae. Nature (1983) 3.43

Cancer and genomics. Nature (2001) 3.15

An SNP map of human chromosome 22. Nature (2000) 2.99

Production of soluble MHC class II proteins with covalently bound single peptides. Nature (1994) 2.98

BRCA2 mutations in primary breast and ovarian cancers. Nat Genet (1996) 2.91

Data mining using the Catalogue of Somatic Mutations in Cancer BioMart. Database (Oxford) (2011) 2.84

Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene (2007) 2.83

Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet (1997) 2.77

The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem (1998) 2.71

High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci U S A (2000) 2.70

Thyroid dysfunction in a prospectively followed series of patients with progressive systemic sclerosis. J Endocrinol Invest (1990) 2.70

Mutations defining functional regions of the superantigen staphylococcal enterotoxin B. J Exp Med (1992) 2.38

Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst (1998) 2.33

Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. Nat Genet (2000) 2.26

Altered surfactant homeostasis and alveolar type II cell morphology in mice lacking surfactant protein D. Proc Natl Acad Sci U S A (1998) 2.22

The genetics of breast cancer susceptibility. Annu Rev Genet (1998) 2.21

Regulation of NMDA receptor desensitization in mouse hippocampal neurons by glycine. Nature (1989) 2.05

[Laparoscopic cholecystectomy in day care; implementation of a guideline for clinical practice]. Ned Tijdschr Geneeskd (2003) 2.03

The extent of linkage disequilibrium in four populations with distinct demographic histories. Am J Hum Genet (2000) 2.03

Recommendations for spacing of test chemical concentrations in the mouse lymphoma tk mutation assay (MLA) Mutat Res (1998) 2.01

A polymorphic stop codon in BRCA2. Nat Genet (1996) 1.95

Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour. J Med Genet (2005) 1.94

Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet (1998) 1.88

Misidentified cell. Nature (1989) 1.81

AutoCSA, an algorithm for high throughput DNA sequence variant detection in cancer genomes. Bioinformatics (2007) 1.80

Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet (1996) 1.79

Identification of a new subclass of Alu DNA repeats which can function as estrogen receptor-dependent transcriptional enhancers. J Biol Chem (1995) 1.78

A kinetic analysis of the modulation of N-methyl-D-aspartic acid receptors by glycine in mouse cultured hippocampal neurones. J Physiol (1990) 1.76

Low frequency of somatic mutations in the LKB1/Peutz-Jeghers syndrome gene in sporadic breast cancer. Cancer Res (1998) 1.73

Somatic mutations of KIT in familial testicular germ cell tumours. Br J Cancer (2004) 1.64

The physical maps for sequencing human chromosomes 1, 6, 9, 10, 13, 20 and X. Nature (2001) 1.63

Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis. Infect Immun (2000) 1.63

The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res (2000) 1.62

AIDS vaccine development. Science (1998) 1.62

The BRC repeats are conserved in mammalian BRCA2 proteins. Hum Mol Genet (1997) 1.62

Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. J Clin Pathol (1995) 1.61

Spine radiographs in patients with low-back pain. An epidemiological study in men. J Bone Joint Surg Am (1984) 1.60

A multicenter analysis of percutaneous discectomy. Spine (Phila Pa 1976) (1990) 1.53

Genetic alterations in 'normal' luminal and myoepithelial cells of the breast. J Pathol (1999) 1.50

The gene for Darier's disease maps to chromosome 12q23-q24.1. Hum Mol Genet (1993) 1.47

Marihuana psychosis. Acute toxic psychosis associated with the use of Cannabis derivatives. JAMA (1969) 1.47

Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res (1998) 1.46

BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells. Cell Growth Differ (1996) 1.45

Structure of canine pulmonary surfactant apoprotein: cDNA and complete amino acid sequence. Proc Natl Acad Sci U S A (1985) 1.45

The gene for cherubism maps to chromosome 4p16.3. Am J Hum Genet (1999) 1.43

Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer. Am J Hum Genet (1997) 1.42

CXC chemokines generate age-related increases in neutrophil-mediated brain inflammation and blood-brain barrier breakdown. Curr Biol (1998) 1.41

Potency preservation following conformal radiotherapy for localized prostate cancer: impact of neoadjuvant androgen blockade, treatment technique, and patient-related factors. Cancer J Sci Am (1999) 1.39

Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res (1998) 1.36

Constitutional translocation breakpoint mapping by genome-wide paired-end sequencing identifies HACE1 as a putative Wilms tumour susceptibility gene. J Med Genet (2009) 1.35

Integrin alpha 4 beta 1-mediated melanoma cell adhesion and migration on vascular cell adhesion molecule-1 (VCAM-1) and the alternatively spliced IIICS region of fibronectin. J Biol Chem (1994) 1.34

Mass psychogenic illness following tetanus-diphtheria toxoid vaccination in Jordan. Bull World Health Organ (2001) 1.34

A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Nat Genet (1992) 1.34

Release probability modulates short-term plasticity at a rat giant terminal. J Physiol (2000) 1.33

LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition. Br J Cancer (2009) 1.33

The impact of immunization control activities on measles outbreaks in middle and low income countries. Int J Epidemiol (1997) 1.33

Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13. Br J Cancer (1995) 1.33

A gene for lymphedema-distichiasis maps to 16q24.3. Am J Hum Genet (1999) 1.32

Cell cycle control of BRCA2. Cancer Res (1996) 1.32

Evidence for a familial Wilms' tumour gene (FWT1) on chromosome 17q12-q21. Nat Genet (1996) 1.30

Competitive binding of vascular cell adhesion molecule-1 and the HepII/IIICS domain of fibronectin to the integrin alpha 4 beta 1. J Biol Chem (1994) 1.29

Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer. Mol Carcinog (1996) 1.27

Detection of allelic imbalance indicates that a proportion of mammary hyperplasia of usual type are clonal, neoplastic proliferations. Lab Invest (1996) 1.27

Inherited susceptibility to colorectal adenomas and carcinomas: evidence for a new predisposition gene on 15q14-q22. Gastroenterology (1999) 1.26

The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators. Cancer Res (2000) 1.25

BRCA1 expression is not directly responsive to estrogen. Oncogene (1997) 1.24

Lack of neutralizing antibodies to caprine arthritis-encephalitis lentivirus in persistently infected goats can be overcome by immunization with inactivated Mycobacterium tuberculosis. J Virol (1984) 1.23

Sleep problems in handicapped children: a preliminary study. J Child Psychol Psychiatry (1986) 1.22

Loss of heterozygosity in lobular carcinoma in situ of the breast. Clin Mol Pathol (1995) 1.21

Familial cylindromatosis (turban tumour syndrome) gene localised to chromosome 16q12-q13: evidence for its role as a tumour suppressor gene. Nat Genet (1995) 1.21

Production and characterization of SIV envelope-specific rhesus monoclonal antibodies from a macaque asymptomatically infected with a live SIV vaccine. AIDS Res Hum Retroviruses (1998) 1.20